Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
This carefully designed combination includes GHK-Cu (copper peptide complex), BPC-157 (stable gastric pentadecapeptide), Thymosin beta-4 (actin-binding polypeptide), and KPV (anti-inflammatory tripeptide), each contributing unique molecular mechanisms to create a synergistic research platform for advanced peptide studies
Administer different peptides separately rather than mixing in one syringe
WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use
People with middle- and late-stage dementia can't usually drive, cook, or live alone
Overall, the benefits of using BPC-157 Thymosin Beta 4 peptide capsules include improved stability, absorption, convenience, and practicality for researchers investigating peptide therapy
US$ 20.78
US$ 24.22
US$ 20.88
US$ 25.59
US$ 22.55
